About Axbio
Axbio is a company based in Shenzhen (China) founded in 2016 by Hui Tian. Axbio has raised $200 million across 2 funding rounds from investors including SDIC, CBC Group and 5Y Capital. Axbio operates in a competitive market with competitors including Guardant Health, GRAIL, Thrive Earlier Detection, Delfi Diagnostics and BillionToOne, among others.
- Headquarter Shenzhen, China
- Founders Hui Tian
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$200 M (USD)
in 2 rounds
-
Latest Funding Round
$100 M (USD), Series B
Jun 20, 2022
-
Investors
SDIC
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Axbio
Unlock access to complete
Funding Insights of Axbio
Axbio has successfully raised a total of $200M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Axbio
Axbio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include SDIC, CBC Group and 5Y Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
A venture capital firm focused on technology and innovation investments.
|
Locked | Locked | Locked | |
|
Private equity investments are managed by Yunfeng Capital in China.
|
Locked | Locked | Locked |
Investor details for Axbio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Axbio
Investment portfolio details for Axbio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Axbio
Detailed financials for Axbio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Axbio Comparisons
Peer comparison for Axbio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Axbio
Axbio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Thrive Earlier Detection, Delfi Diagnostics and BillionToOne, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Blood-based liquid biopsy tests for multiple cancer detection are provided.
|
|
| Locked | Locked | Locked |
Provider of DNA sequencing for cancer detection
|
|
| Locked | Locked | Locked |
Provider of cell-free cancer liquid biopsy test
|
|
| Locked | Locked | Locked |
Liquid biopsy for post-cancer surgery tumor monitoring is provided.
|
Detailed competitors of Axbio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Axbio
Complete news archive for Axbio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Axbio
Axbio was founded in 2016 and raised its 1st funding round 5 years after it was founded.
Axbio is headquartered in Shenzhen, China. It is registered at Shenzhen, Guangdong, China.
Hui Tian is the current CEO of Axbio. They have also founded this company.
Axbio is a funded company, having raised a total of $200M across 2 funding rounds to date.
Developer of a lab on chip microfluidic platform for sequencing and molecular diagnostics using AI. The companys technology platform can carry out single-molecule real-time sequencing without the amplification of nucleic acid. Each nanochip contains many nanopores having an active microfluidic system. This technology can also be used in disease screening and microbial detection.
Axbio's top competitors include Guardant Health, GRAIL and BillionToOne.
Axbio has 7 investors. Key investors include SDIC, CBC Group, 5Y Capital, Yunfeng Capital, and AstraZeneca China.